TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06433440

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PVRV
Description: Group-1 will receive PVRV ID on on the following days: Day0, Day3, Day7, while group-2 will receive PVRV IM on Day0, Day3, Day7, Day14, and Day28.
Study: NCT01075399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [F 18]HX4
Description: Approximately forty (40) patients who have diagnosis confirmed by histopathological examination of tumor tissue from head/neck, lung, liver, rectal or cervical cancers and will receive chemotherapy, radiation therapy or chemoradiotherapy, will be imaged under PET/CT with \[F 18\]HX4
Study: NCT03985189

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ME-401
Description: \[Phase 1 study (DLT evaluation)\] ME-401 will be administered at 2 dosages as 45 mg (Cohort 1) or 60 mg (Cohort 2), daily oral administration, QD, and the trial will be initiated at Cohort 1, and medical specialists and the Efficacy and Safety Assessment Committee as needed will decide whether the Cohort will be shifted to the next stage based on their assessment of the safety and tolerability.~\[Roll over study\] 60 mg ME-401 will be administrated on intermittent schedule (1 week on and 3 week off in every 4-week cycle)and will continue until the prescribed mediation in ME-401-004 study is completed or discontinuation criteria are met.
Study: NCT02267213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipotecan
Description: Administer 40mg Lipotecan at D1, D8, D15 of each cycle.
Study: NCT04353388

Intervention type: DIAGNOSTIC_TEST
Intervention: CBC-DIFF Monocyte Volume Width Distribution (MDW)
Description: MDW measurement will be used to detect sepsis. Results will not be used to manage patients.
Study: NCT01329588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Monthly antibiotic
Description: Azithromycin 1g per os once at months 1, 4 and 7 Ciprofloxacin 500 mg per os once at months 2, 3, 5, 6, 8 and 9
Study: NCT03378778

Intervention type: PROCEDURE
Intervention: Root canal treatment
Description: Root Canal Treatment followed by Ceramic Onlay restoration

Intervention type: PROCEDURE
Intervention: Root canal treatment
Description: Root Canal Treatment followed by Ceramic Onlay restoration

Intervention type: PROCEDURE
Intervention: Root canal treatment
Description: Root Canal Treatment followed by Ceramic Onlay restoration

Intervention type: PROCEDURE
Intervention: Root canal treatment
Description: Root Canal Treatment followed by Ceramic Onlay restoration
Study: NCT00848068

Intervention type: OTHER
Group type: OTHER
Intervention: FID 114657
Description: artificial tears

Intervention type: OTHER
Group type: OTHER
Intervention: FID 114657
Description: artificial tears

Intervention type: OTHER
Group type: OTHER
Intervention: OPTIVE Lubricant Eye Drops
Description: artificial tears

Intervention type: OTHER
Group type: OTHER
Intervention: OPTIVE Lubricant Eye Drops
Description: artificial tears
Study: NCT02223013

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BIBV 308 SE solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBV 308 SE capsule L

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBV 308 SE capsule S
Study: NCT02880332

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: During usual care therapy, children and their parents will receive a +/- 1 h session containing bio-medical directed education and information about the gastro-intestinal system and its function. This knowledge will be brought to bear with a hypnotic journey through their body, guided by a nurse with specific expertise in pediatric abdominal pain. Furthermore, the influence of stress on the gastro-intestinal system will be explained, combined with exercises to practise abdominal respiration.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: During usual care therapy, children and their parents will receive a +/- 1 h session containing bio-medical directed education and information about the gastro-intestinal system and its function. This knowledge will be brought to bear with a hypnotic journey through their body, guided by a nurse with specific expertise in pediatric abdominal pain. Furthermore, the influence of stress on the gastro-intestinal system will be explained, combined with exercises to practise abdominal respiration.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain Neuroscience education
Description: This therapy will consist out of a +/- 1 h one-on-one educational session about neurophysiology of pain, adjusted to the child's comprehension status. The content of the education sessions and pictures will be based on the book Explain Pain by Butler and Moseley and will include explanation and reassurance about the cause of pain, a brief summary of relevant pain mechanisms and the integral role of psychosocial and physical factors in precipitating and maintaining pain. Metaphors, leaflets, books and audio-visual media will be used in a supportive function to consolidate verbally transmitted information. Parents will participate in the PNE session as well.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Extra care
Description: During this therapy session, all the patient's/ parents questions that arose from the previous session (Usual care) will be answered. Afterwards, the educated content from this previous session will be revised. Nothing new will be taught. At the end of the session, the participant will be asked to demonstrate the previously learned exercises on abdominal respiration. If the exercises are not well performed, the therapist will correct them.
Study: NCT03109652

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: On the day of operation, same dose of IV tranexamic acid(TXA) is given to all subjects in three study groups. Oral TXA is given from postoperative day 1 only to experimental groups. Duration of oral TXA administration is different between two experimental groups. (5 days in IV TXA and Oral TXA 5 days group and 2 days in IV TXA and Oral TXA 2 days group)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: On the day of operation, same dose of IV tranexamic acid(TXA) is given to all subjects in three study groups. Oral TXA is given from postoperative day 1 only to experimental groups. Duration of oral TXA administration is different between two experimental groups. (5 days in IV TXA and Oral TXA 5 days group and 2 days in IV TXA and Oral TXA 2 days group)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: On the day of operation, same dose of IV tranexamic acid(TXA) is given to all subjects in three study groups. Oral TXA is given from postoperative day 1 only to experimental groups. Duration of oral TXA administration is different between two experimental groups. (5 days in IV TXA and Oral TXA 5 days group and 2 days in IV TXA and Oral TXA 2 days group)
Study: NCT00637832

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisolone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: yttrium Y 90 ibritumomab tiuxetan
Study: NCT01329588

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Monthly placebo
Description: Azithromycin placebo (sugar pill) per os once at months 1, 4 and 7 Ciprofloxacin placebo (sugar pill) per os once at months 2, 3, 5, 6, 8 and 9
Study: NCT03488225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IT or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given IV or PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV
Study: NCT03065478

Intervention type: DIETARY_SUPPLEMENT
Intervention: OnLife
Description: Daily dosing of dietary supplement OnLife

Intervention type: DIETARY_SUPPLEMENT
Intervention: OnLife
Description: Daily dosing of dietary supplement OnLife
Study: NCT01834768

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplerenone
Study: NCT02296203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan
Study: NCT03758703

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre-recorded music intervention group
Description: Refer to the arm/group descriptions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pre-recorded soothing poetry group
Description: Refer to the arm/group descriptions.
Study: NCT03488225

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inotuzumab Ozogamicin
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptopurine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IT, IV or PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study: NCT02570672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Subjects will be randomized to metformin titrated to 1000mg twice daily as tolerated.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will randomized to placebo will receive placebo
Study: NCT02561741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COV155
Description: COV155 tablets
Study: NCT04364464

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riociguat (Adempas, BAY 63-2521)
Description: 0.5 mg riociguat as an immediate-release (IR) tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riociguat (Adempas, BAY 63-2521)
Description: 0.5 mg riociguat as an immediate-release (IR) tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riociguat (Adempas, BAY 63-2521)
Description: 0.5 mg riociguat as an immediate-release (IR) tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riociguat (Adempas, BAY 63-2521)
Description: 0.5 mg riociguat as an immediate-release (IR) tablet
Study: NCT01879033

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Reactive hyperemia peripheral artery tonometry (Rh-PAT)
Description: Pulse volume is measured by a finger plethysmographic device which are sensed by a pressure transducer and transferred to a computer where the signal is amplified, displayed and stored (EndoPAT, Itamar Medical). Fingertip probes are placed on the index finger of both hands and 5 minutes of baseline recording are obtained. Blood flow is then occluded in one arm for 5 minutes, using a standard blood pressure cuff. Recording continues in both fingers during occlusion and for 5 minutes after release of the cuff. The RH-PAT index is calculated as the ratio of the average pulse amplitude in the post-hyperemic phase divided by the average baseline amplitude, with normalization to the signal in the control arm to compensate for any systemic changes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Reactive hyperemia peripheral artery tonometry (Rh-PAT)
Description: Pulse volume is measured by a finger plethysmographic device which are sensed by a pressure transducer and transferred to a computer where the signal is amplified, displayed and stored (EndoPAT, Itamar Medical). Fingertip probes are placed on the index finger of both hands and 5 minutes of baseline recording are obtained. Blood flow is then occluded in one arm for 5 minutes, using a standard blood pressure cuff. Recording continues in both fingers during occlusion and for 5 minutes after release of the cuff. The RH-PAT index is calculated as the ratio of the average pulse amplitude in the post-hyperemic phase divided by the average baseline amplitude, with normalization to the signal in the control arm to compensate for any systemic changes.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Blood levels for glucose, insulin, lipids and adipocytokines
Description: A fasting laboratory evaluation will include chemistry panel (basic metabolic, liver function tests), CBC, lipid profile, urinalysis and HbA1c. All obese recruited subjects after a 12 hour fast will undergo an OGTT using a glucose load of 1.75 g/kg body weight with a maximum of 75 g. Blood samples will be collected for insulin, glucose, leptin, adiponectin, hsCRP and FFA. Serum and urine will be stored at -70 degrees Centigrade for measuring markers of oxidative stress and adipocytokines (including TNF-α, PAI-1)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blood levels for glucose, insulin, lipids and adipocytokines
Description: A fasting laboratory evaluation will include chemistry panel (basic metabolic, liver function tests), CBC, lipid profile, urinalysis and HbA1c. All obese recruited subjects after a 12 hour fast will undergo an OGTT using a glucose load of 1.75 g/kg body weight with a maximum of 75 g. Blood samples will be collected for insulin, glucose, leptin, adiponectin, hsCRP and FFA. Serum and urine will be stored at -70 degrees Centigrade for measuring markers of oxidative stress and adipocytokines (including TNF-α, PAI-1)
Study: NCT03490396

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gelclair
Description: Polyvinylpyrrolidone (PVP) and Sodium Hyaluronate-Containing Oral Gel

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gelclair
Description: Polyvinylpyrrolidone (PVP) and Sodium Hyaluronate-Containing Oral Gel
Study: NCT02664025

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: vaginal examination simulator
Study: NCT02747719

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Light and exercise
Description: Exposure to light and exercise
Study: NCT03490396

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: First® Mouthwash BLM
Description: Viscous Lidocaine, Diphenhydramine, and Aluminum-magnesium Hydroxide/Simethicone Antacid Suspension Mouthwash
Study: NCT01500967

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shi-style cervical manipulations
Description: Shi-style cervical manipulation is a spinal manipulation for cervical radiculopathy.It is a kind of traditional chinese massage and can dredge the meridian.Patients are treated every day for 30 minutes.Seven times at one course and totally there are two courses.3 times a week, once the other day（except the weekends）,30 minutes, 2 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cervical Traction control
Description: 6kg to 10kg, 3 times a week, once the other day（except the weekends）,20 minutes, 2 weeks.
Study: NCT02538692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tong-Xie-Yao-Fang
Description: Tong-Xie-Yao-Fang is a traditional Chinese formula. It is used for diarrhea management.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo is the same as Tong-Xie-Yao-Fang in appearance.
Study: NCT03871725

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Sonodynamic therapy (SDT)
Description: Sinoporphyrin sodium (DVDMS) as sonosensitizer, is dissolved in 0.9% sodium solution for following skin test and intravenous injection. 0.01mg/ml DVDMS solution (0.1ml) is prepared for skin test followed by 0.04 mg/ml DVDMS solution intravenous injection (0.2mg/kg).The target atherosclerotic lesions are marked on the corresponding skin with ultrasound guidance and underwent ultrasound exposure after 4 hours incubation. The therapeutic ultrasonic transducer is fixed to the marked skin site for 15min of each lesion. Ultrasound parameters included intensity of 1.6W/cm2 for carotid lesions, resonance frequency: 1.0 MHz and duty factor: 30%.
Study: NCT02860117

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine continuous infusion
Description: Ketamine 0.1% 250mL continuous infusion (0,2ml/kg/h)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo continuous infusion (0,2 ml/kg/h)
Study: NCT02271711

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT01820221

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Suture vs. staples closure method after c-section in obese women.
Description: Random card draw to either suture skin closure or staple skin closure arm of study.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Suture vs. staples closure method after c-section in obese women.
Description: Random card draw to either suture skin closure or staple skin closure arm of study.
Study: NCT02271711

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Natural Killer Cell Therapy
Description: Given autologous ex-vivo expanded NK cells IV
Study: NCT04326439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 100 mg/m²/dose every 12 hours IV Days 1-10

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 100 mg/m²/dose every 12 hours IV Days 1-10

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: 50 mg/m²/dose IV Days 1, 3, 5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: 50 mg/m²/dose IV Days 1, 3, 5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erwinase
Description: 25,000 International Units/m²/dose IM Days 2, 9

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erwinase
Description: 25,000 International Units/m²/dose IM Days 2, 9

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 150 mg/m²/dose IV Days 1-5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 150 mg/m²/dose IV Days 1-5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin
Description: Administered as a single 3 mg/m2 dose of GO to be given between days 6-10 during Induction I for patients with CC genotype, in addition to ADE therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin
Description: Administered as a single 3 mg/m2 dose of GO to be given between days 6-10 during Induction I for patients with CC genotype, in addition to ADE therapy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem cell transplantation (SCT)
Description: Transplantation of multipotent hematopoietic stem cells from bone marrow

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: 200 mg/m2/dose daily, rounded to accommodate tablet size. The maximum dose will be 400 mg. Days 7 through 34.
Study: NCT03493022

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test Granola
Description: 50.5 Test Granola

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Granola
Description: 54.3 Control Granola
Study: NCT05616429

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Alcat based personal diet
Description: Alcat based personalized diet with dietician supervision and follow-up + usual care

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Standard balanced diet
Description: Sham standard balanced diet with dietician supervision and follow up + usual care.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: usual care
Description: usual care

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: usual care
Description: usual care
Study: NCT01537276

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: diagnose under real-time fluoroscopy
Description: radiologists evaluating the tubal patency under fluoroscopy real-timely.Findings of fluoroscopy were blind to the investigators when the static radiographs were re-analyzed by the same team of radiologists.
Study: NCT01242501

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 60 Minute HIV/STI risk reduction counseling.Single 60 min Social Cognitive Theory-based counseling.
Description: Single session risk reduction counseling delivered in STI clinic settings in South Africa.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 20-Min education session
Description: Patients receive a single 20 min education session for STI/HIV informationSingle brief HIV/STI education only session for men and women receiving sexually transmitted infection clinic services in South Africa. Includes only brief educational information on sexual risks for HIV infection in a single face-to-face counseling session.
Study: NCT04336852

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Flow mediated dilation (brachial and femoral arteries)
Description: Assessment of vascular function of the brachial and femoral arteries.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cerebral vascular reactivity to carbon dioxide (CO2)
Description: Cerebral blood flow responses to increasing partial pressure of CO2

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cerebral vascular function test
Description: Cerebral blood flow responses to a reactive hyperemia stimulus
Study: NCT01909726

Intervention type: OTHER
Intervention: ScreenPlay
Description: Interactive technology
Study: NCT03903367

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl Citrate
Description: standard GA and receive fentanyl infusion 2 mcg/kg/h after tracheal intubation and stopped at the end of the operation ,When HR or MBP increased ≥20% from base line readings, incremental dose of fentanyl will be given (2mcg /kg).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl Citrate
Description: standard GA and receive fentanyl infusion 2 mcg/kg/h after tracheal intubation and stopped at the end of the operation ,When HR or MBP increased ≥20% from base line readings, incremental dose of fentanyl will be given (2mcg /kg).
Study: NCT04151238

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise intervention for cancer patients to increase physical activity during chemotherapy
Description: The duration of the exercise intervention is eight (8) weeks. There will be guided endurance and muscle power training two (2) time weekly. The participants will also be provided with one training program per week for use at home.
Study: NCT03516006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UCMSC
Description: infusion of aUCMSC at day 0, 7, 14, and 21

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UDCA
Description: oral administration of ursodeoxycholic acid (UDCA) 15mg/kg/d

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: UDCA
Description: oral administration of ursodeoxycholic acid (UDCA) 15mg/kg/d